Skip to content

GMP

How GMP Gap Assessment Becomes a CAPA Plan

Planned
StatusPlanned

This article is in preparation.

The topic is planned and the article has not been written yet. Nothing on this page is published technical guidance.

What it will cover

This article will examine how findings from a GMP gap assessment are captured, classified by risk, and turned into engineering responses with defined evidence, owners, and verification steps. It will also explain why a CAPA plan needs closeout evidence rather than a statement that an action was taken.

Working on this topic now?

If this question is live on your project, you do not need to wait for the article. Tell us about the facility and we can discuss it directly.

Related articles and topics

All insights
  • 01GMP

    EU GMP Annex 1 and the Contamination Control Strategy

    What a contamination control strategy (CCS) is under the revised EU GMP Annex 1, what it connects, and how facility design, HVAC, flows, cleaning, monitoring, sterilization, qualification and CAPA feed into one documented strategy.

  • 02Pharma Engineering

    Pharmaceutical Water Systems: RO, PW and WFI Explained

    How a pharmaceutical water system is built up from pretreatment through reverse osmosis and polishing to Purified Water, where Water for Injection fits, and why the WFI technology, the loop temperature and the sanitization method are project decisions rather than fixed answers.

Next step

Planning a pharmaceutical project?

Share the product type, the current stage and the main constraints. We will respond with a proposed scope and next steps.

+20 101 171 1700